This review focuses on the methodologies that we have found to be successful with cartilage and bone marrow sources of human cells and comments on the many factors which may enable improved phenotypic performance once the cells are in a fully chondrogenic environment.
These results support the hypothesis that our phenotypic screening approach may enable the generation of new cellulosic ethanologens selected and tailored for specific pretreatment and hydrolysis methods, types of biomass or custom fermentation processes.
Although first insights are upcoming, further research is required to investigate reliable prognostic factors such as age at treatment start, phenotypic presentation, and genotypic characteristics, of which may enable better clinical and therapeutic management of LOPD patients.
The methods reported here may enable to study multiple low-penetrance genetic factors that together determine various quantitative phenotypic traits.
This approach may enable a comprehensive understanding of compound in terms of mechanism-of-action, associated pathways and phenotypic profile.
Moreover, this system may enable the development of effective drugs that are applicable for most genetic variants of DMD by phenotypic screening based on early pathogenesis.
Each may enable or constrain the partnership.
This may enable effective disease management.
Novel injury biomarkers may enable earlier diagnosis.
Live-fly phenotyping greatly simplifies selection protocols by enabling phenotypic analysis before breeding.
